Project description
Contactless comprehensive solution for the monitoring of sleep apnoea
More than 30% of the world's population suffers from different forms of sleep disorders. Sleep apnoea is a serious sleep disorder when a person’s breathing is interrupted during sleep. The untreated sleep apnoea increases the risk for sudden cardiac arrest, stroke, and cardiovascular mortality. The recently developed innovative platform is user-friendly and based on a patient-centred solution with advanced software and hardware engineering. In contrast to the current approach, the developed contactless solution enables medical professionals to screen patients for sleep apnoea in their most natural sleep environment and behaviour. The EU-funded Sleepiz project aims to validate the commercial feasibility of the platform, including market analysis, cost-benefit benchmarking, and stakeholder outreach.
Objective
Sleep loss is an aggravating factor in the global burden of disease with collateral effects on cardiovascular and mental health as well as injury and death through human error.
State of the art clinical diagnostic tools that measure sleep data are expensive, complex to interpret, and stressful for the patients. Today’s most accurate diagnostic tools require patients to strap electrodes and chest monitors to their body and undergo overnight testing, often in a clinic.
Sleepiz AG has developed a breakthrough solution in clinical sleep-monitoring solutions. Our innovation, Sleepiz, is a contact-free sensor-based diagnostic device for sleep specialists and clinics. It can analyze patients’ vital signs and environmental measurements without touching the patient. We use test results to continuously feed and improve our self-learning algorithms.
Sleep specialists will prescribe Sleepiz to patients to use in their homes. Doctors can view the results remotely and in real-time. We will charge clinics a fee per session in line with today’s diagnostic costs; our solution will be up to 2x more time- and cost-efficient.
The approval of Sleepiz as a clinical diagnostic device in the EU and US, together with the ramp-up of commercial activities and stakeholder outreach, comprise the major objectives of this project.
The goal of phase 1 is to further validate product-market fits, along with planning and allocating resources for clinical validation trials during phase 2.
Sleepiz AG is a Swiss startup comprised of young entrepreneurs and innovators. We have already created great interest: 4 hospitals that use clinical-grade sleep diagnosis tools - a market worth close to €5Bn – want to validate our system. An advisory board of leading experts in related tech and innovation fields will help guide our go-to-market plan.
We project annual sales revenues of €34.16M by year 5 after market launch, and we forecast directly creating 197 jobs.
Fields of science
- medical and health sciencesclinical medicinepsychiatrysleep disorders
- natural sciencescomputer and information sciencesdata science
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicineneurologydementia
- medical and health sciencesbasic medicineneurologystroke
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
8008 ZURICH
Switzerland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.